Product Reports Resources Pricing Login Book a demo

TreeFrog Therapeutics

Biotech & Life Sciences · Pessac, France · Founded 2018

TreeFrog Therapeutics is a French biotechnology company specializing in cell therapy. The company has developed a proprietary technology called C-Stem, which enables the mass production of high-quality stem cells. This technology addresses a major challenge in the field of cell therapy, which is the ability to produce large quantities of cells for clinical and commercial use. The company's business model is based on developing its own pipeline of cell therapies and collaborating with other companies in the field. TreeFrog Therapeutics is currently focused on developing treatments for neurodegenerative diseases, such as Parkinson's disease, and has a pipeline of therapeutic candidates in preclinical development. The company operates in the regenerative medicine market, which is a rapidly growing segment of the healthcare industry. TreeFrog Therapeutics serves a variety of clients, including pharmaceutical and biotechnology companies, as well as academic research institutions. The company's C-Stem technology is available for licensing, and TreeFrog Therapeutics also provides cell manufacturing services to its partners. Keywords: cell therapy, stem cells, regenerative medicine, biotechnology, C-Stem, neurodegenerative diseases, Parkinson's disease, cell manufacturing, preclinical development, licensing.

Investors

10 investors on TreeFrog Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 7 investors entered at this stage
Bpifrance
XAnge
Aquitaine Science Transfert
Irdi Capital Investissement
Galia Gestion
French Government
European Innovation Council
Series A 2 investors entered at this stage
Bristol-Myers Squibb
Leonard Green & Partners
Series B+ 1 investor entered at this stage
European Investment Bank

Global footprint

Where TreeFrog Therapeutics has talent and traffic

Workforce by country
5 countries with
team presence
🇫🇷 France88.9%
🇺🇸 United States9.2%
🇩🇪 Germany0.7%
🇯🇵 Japan0.7%
🇨🇭 Switzerland0.7%
5 countries shown
Web traffic by country
3.7K monthly visits
across markets
🇺🇸 United States51.4%
🇫🇷 France35.1%
🇬🇧 United Kingdom13.5%
Top 3 markets shown

Talent graph

The shape of TreeFrog Therapeutics's talent

Dealroom maps TreeFrog Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

14 team members profilednamed & role-tagged by Dealroom
160 employeestotal headcount
8 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock TreeFrog Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about TreeFrog Therapeutics

An AI-synthesized read of the highest-engagement posts about TreeFrog Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TreeFrog Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.